Pulse Biosciences Reaches Enrollment Target in Atrial Fibrillation Study

Pulse Biosciences announced its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The study is evaluating the nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation using the company's nano-PFA technology.